Carbidopa/levodopa/entacapone

DRUG4 trials

Sponsors

Novartis Pharmaceuticals, Novartis

Conditions

Parkinson's DiseaseParkinson's Disease With End of Dose Wearing Off

Phase 3

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy

CompletedNCT00099268

Novartis PharmaceuticalsParkinson's Disease

Start: 2004-09-30End: 2008-11-30Updated: 2012-04-23

Phase 4

Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease

CompletedNCT00219284

Novartis PharmaceuticalsParkinson's Disease With End of Dose Wearing Off

Start: 2005-01-31End: 2008-07-31Updated: 2017-03-30

Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off

WithdrawnNCT00601978

Novartis PharmaceuticalsParkinson's Disease

Start: 2008-08-31End: 2009-11-30Updated: 2012-04-30

Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off

TerminatedNCT00642356

NovartisParkinson's Disease

Start: 2008-03-31End: 2009-05-31Updated: 2011-02-18